← Back to Calendar

Rhythm Pharmaceuticals Q4 2025 Earnings

Rhythm Pharmaceuticals · $RYTM

Standard Review Earnings

PDUFA Date

February 26, 2026

Time Remaining

26d ago

Review Type

Standard (10 mo)

Indication

Q4 2025 earnings + IMCIVREE acquired HO PDUFA update

Key Notes

Q4 2025 earnings reported February 26, 2026. IMCIVREE Q4 revenue $57.3M (FY2025 $194.8M, +50% YoY). FDA PDUFA March 20, 2026 for acquired hypothalamic obesity (sNDA). EMA CHMP opinion expected Q2 2026. Phase 3 EMANATE topline data expected Q1 2026.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar